The Korean Journal of Applied Statistics (응용통계연구)

The Korean Statistical Society (한국통계학회)
권호 표지
DOI QR코드

DOI QR Code

Investigation on the modified continual reassessment method in phase I clinical trial

1상 임상실험에서 수정된 CRM에 대한 연구

  • 강승호 (이화여자대학교 통계학과)
  • Published : 2002.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

In this paper we consider the modified continual reassessment method in which a cohort consists of three patients. Simulation has been a main research tool in the investigation of CRM. In this paper we propose complete enumeration as an alternative of simulation. Using new method we show that the expected toxicity rate at the MTD converges to the target toxicity rate well as the sample size increases.

최근에 1상 임상실험 에서 사용되는 continual reassessment method (CRM)에 대한 연구가 활발히 이루어지고 있다. 본 논문에서는 세 명의 환자를 하나의 환자 군으로 삼아 동일한 용량을 투여하는 수정된 CRM에 대한 연구를 실행하였다. 지금까지 CRM에 대한연구는 대부분 시뮬레이션에 의존하여 왔지만, 본 논문에서는 모든 가능한 경우를 고려하는 방법(complete enumeration)을 사용하였다. 이 새로운 방법은 시뮬레이션을 대체할 유용한 방법이라 사료된다. 이 새로운 방법을 이용하여, 용량독성곡선이 logistic함수, hyperbolic tangent 함수, power 함수일 때, 수정된 CRM에서 결정한 최대허용용량에서의 독성 확률이 목표 독성 확률로 잘 수렴함을 보였다. 하지만, 실험 전에 용량들을 적절히 선택하지 못하면, 최대허용용량에서의 독성 확률이 목표 독성 확률과 상당한 차이를 낼 수도 있음을 발견하였다.

Keywords

References

  1. The Korean Journal of Applied Statistics v.6 여러 약제의 상승효과 검정을 위한 통계적 기법 김병수;김주항;김경미;최정주
  2. The Korean Journal of Applied Statistics v.12 층화된 임상시험에서 생존분포의 비교를 위한 표본수의 결정 김선우;박미라;이재원
  3. The Korean Journal of Applied Statistics v.9 임상시험에서 치료율 비교를 위한 집단축차검정법에 관한 고찰 박경미;이재원
  4. The Korean Journal of Applied Statistics v.11 생존함수의 비교연구를 위한 표본수의 결정 박미라;김선우;이재원
  5. The Korean Journal of Applied Statistics v.10 임상실험에서 그룹축차방법들의 비교 서의훈;안성진;임동훈
  6. The Korean Journal of Applied Statistics v.12 두 개의 제제형식과 기존제제간의 생물학적 동등성 검정 오현숙;고승곤;김정일;박상규
  7. Statistics in Medicine v.17 An evaluation of Phase I cancer clinical trial designs Ahn, C. https://doi.org/10.1002/(SICI)1097-0258(19980730)17:14<1537::AID-SIM872>3.0.CO;2-F
  8. European Journal of Obstetrics & Gynecology and Reproductive Biology v.77 Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth Dongen, P. W. J.;Verbruggen, M. M.;Groot, A. N. J. A.;Roosmalen, J.;Sporken, J. M. J.;Schulz, M. https://doi.org/10.1016/S0301-2115(97)00260-1
  9. Journal of Clinical Oncology v.18 no.24 Phase I and Pharmacokinetic study of irofulven, a novel mushroomderived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies Eckhardt, G.;Baker, S.;Britten, C. D.;Hidalgo, M.;Siu, L.;Hammand, L. A.;Villalona-Calero, M. A.;Feltan, S.;Drengler, R.;Kuhn, J. G.;Clark, G. M.;Smith, S. L.;MacDonald, J. R.;Smith, C.;Moczygemba, J.;Weitman, S.;Van Hoff, D. D.;Rowinsky, E. K. https://doi.org/10.1200/JCO.2000.18.24.4086
  10. Journal of Biopharmaceutical Statistics v.4 Practical modifications of the continual reassessment method for phase I cancer clinical trials Faries, D. https://doi.org/10.1080/10543409408835079
  11. Journal of Clinical Oncology v.18 no.24 Phase I does finding study of a new taxane, RPR 10988A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors Gelmon, K. A.;Latreille, J.;Tolcher, A.;Genier, L.;Fisher, B.;Farand, D.;D'Alosio, S.;Vernillet, L.;Daigneault, L.;Lebecq, A.;Besenval, M.;Eisenhauer, E. https://doi.org/10.1200/JCO.2000.18.24.4098
  12. Statistics in Medicine v.14 Some practical improvements in the continual reassessment method for phase I studies Goodman, S.;Zahurak, M.;Piantadosi, S. https://doi.org/10.1002/sim.4780141102
  13. Cancer Chemotherapy and Pharmacology v.42 Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants Grossman, S. A.;Hochberg, F.;Fisher, J.;Chen, T. L.;Kim, L.;Gregory, R.;Grochow, L. B.;Piantadosi, S. https://doi.org/10.1007/s002800050794
  14. Drug Information Journal v.35 no.4 The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design Kang, S. H.;Ahn, C. W. https://doi.org/10.1177/009286150103500416
  15. Statistics in Medicine v.14 An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses Moller, S. https://doi.org/10.1002/sim.4780140909
  16. Statistics in Medicine v.10 Methods for dose finding studies in cancer trials: A review and results of a Monte Carlo study O'Quigley, J.;Chevret, S. https://doi.org/10.1002/sim.4780101104
  17. Biometrics v.46 Continual reassessment method: A practical design for phase I clinical trials in cancer O'Quigley, J.;Pepe, M.;Fisher, M. https://doi.org/10.2307/2531628
  18. The Korean Communications in Statistics v.6 Estimation of Maximal Tolerated Dose in Sequential Phase I Clinical Trials Park, I.;Song, H.
  19. Cancer Chemotherapy and Pharmacology v.44 A phase I evaluation of multitargeted antifolate(MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment for dose escalation Rinaldi, D. A.;Kuhn, J. G.;Burris, H. A.;Dorr, F. A.;Rodriguez, G.;Eckhardt, S. G.;Jones, S.;Woodworth, J. R.;Baker, S.;Langley, C.;Mascorro, D.;Abrahams, T.;Von Hoff D. D. https://doi.org/10.1007/s002800050992

Cited by

  1. Maximum Tolerated Dose Estimation Applied Biased Coin Design in a Phase I Clinical Trial vol.19, pp.6, 2012, https://doi.org/10.5351/CKSS.2012.19.6.877
  2. Maximum Tolerated Dose Estimate by Curve Fitting in Phase I Clinical Trial vol.18, pp.2, 2011, https://doi.org/10.5351/CKSS.2011.18.2.179